Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
Kidney Cancer · 2017
DOI: 10.3233/kca-160002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Cancer, 2017. Verfasst von Steven M Yip und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Treatment outcomes are poorly characterized in patients with metastatic chromophobe renal cell cancer (chrRCC), a subtype of renal cell carcinoma.
Objective
This retrospective series aims to determine metastatic chrRCC treatment outcomes in the targeted therapy era.
Methods
A retrospective data analysis was performed using the IMDC dataset of 4970 patients to determine metastatic chrRCC treatment outcomes in the targeted therapy era.
Results
109/4970 (2.2%) patients had metastatic chrRCC out of all patients with mRCC treated with targeted therapy. These patients were compared with 4861/4970 (97.8%) clear cell mRCC (ccRCC) patients. Patients with metastatic chrRCC had a similar OS compared to patients with ccRCC (23.8 months (95% CI 16.7 – 28.1) vs 22.4 months (95% CI 21.4 – 23.4), respectively ( p = 0.0908). Patients with IMDC favorable (18%), intermediate (59%) and poor risk (23%) had median overall survivals of 31.4, 27.3, and 4.8 months, respectively ( p = 0.028).
Conclusions
To the authors’ knowledge, this is the largest series of metastatic chrRCC patients and these results set new benchmarks for survival in clinical trial design and patient counseling. The IMDC criteria risk categories seem to stratify patients into appropriate favourable, intermediate, and poor risk groups, although larger patient numbers are required. It appears that outcomes between metastatic chrRCC and ccRCC are similar when treated with conventional targeted therapies. Patients with metastatic chrRCC can be treated with tyrosine kinase inhibitors and enrolled in clinical trials to further measure outcomes in this rare patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
- Hospital Medica Sur, Mexico City, Mexico.
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
- Medical Oncology, Casa di Cura Pederzoli, Peschiera Del Garda, Peschiera Del Garda (VR), Italy.
- Instituto Oncologico Veneto, Venice, Italy.
- Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Zitieren
APA
Yip, S. M., Ruiz Morales, J. M., Donskov, F., Fraccon, A., Basso, U., Rini, B. I., Lee, J. L., Bjarnason, G. A., Sim, H. W., Beuselinck, B., Kanesvaran, R., Brugarolas, J., Koutsoukos, K., Fu, S. Y. F., Yuasa, T., Davis, I., Alva, A., Kollmannsberger, C., Choueiri, T. K., & Heng, D. Y. C. (2017). Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. https://doi.org/10.3233/kca-160002
Vancouver
Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, et al. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. 2017. doi:10.3233/kca-160002
BibTeX
@article{Yip2017,
author = {Yip, Steven M and Ruiz Morales, Jose M and Donskov, Frede and Fraccon, Anna and Basso, Umberto and Rini, Brian I and Lee, Jae Lyun and Bjarnason, Georg A and Sim, Hao-Wen and Beuselinck, Benoit and Kanesvaran, Ravindran and Brugarolas, James and Koutsoukos, Kostas and Fu, Simon Yuen Fai and Yuasa, Takeshi and Davis, Ian and Alva, Ajjai and Kollmannsberger, Christian and Choueiri, Toni K and Heng, Daniel Y C},
title = {Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)},
journal = {Kidney Cancer},
year = {2017},
doi = {10.3233/kca-160002}
}
EUVIMED